Mahdavi R, Faramarzi E, Seyedrezazadeh E, et al. Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res. 2009 Jul;130(1):1-6.

Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med. 2005 Jan;19(1):17-20.

Choi MA, Kim BS, Yu R. Serum antioxidative vitamin levels and lipid peroxidation in gastric carcinoma patients. Cancer Lett. 1999 Feb 8;136(1):89-93.

Sharma A, Tripathi M, Satyam A, et al. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma. 2009 May;50(5):809-15.

Huijskens MJ, Wodzig WK, Walczak M, et al. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol. 2016;6:8-10.

Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005. Dec;24(4):269-76.

Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ. 1998;316(7145):1661-1662.

Gacitúa TA, Sotomayor CG, Groothof D, et al. Plasma Vitamin C and Cancer Mortality in Kidney Transplant Recipients. J Clin Med. 2019 Nov 23;8(12):2064.

Khanzode SS, Muddeshwar MG, Khanzode SD, et al. Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radic Res. 2004 Jan;38(1):81-5.

White R, Nonis M, Pearson JF, et al. Low Vitamin C Status in Patients with Cancer Is Associated with Patient and Tumor Characteristics. Nutrients. 2020 Aug 5;12(8):2338.

Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998 Dec;9(12):1331-7.

Carr AC, Cook J. Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge. Front Physiol. 2018;9:1182.

Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med. 2007 Jan-Feb;13(1):22-8. Review.

Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008 Sep 15;123(6):1227-39.

Singh K, Bhori M, Kasu YA, Bhat G, Marar T. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity. Saudi Pharm J. 2018 Feb;26(2):177-190.

Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976 Oct;73(10):3685-9.

Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982;23:103-13.

Fritz H, Flower G, Weeks L, et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integr Cancer Ther. 2014 Jul;13(4):280-300.

Nauman G, Gray JC, Parkinson R, et al. Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel). 2018 Jul 12;7(7):89.

Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal. 2013 Dec 10;19(17):2141-56.

Zasowska-Nowak A, Nowak PJ, Ciałkowska-Rysz A. High-Dose Vitamin C in Advanced-Stage Cancer Patients. Nutriens. 2021;13(3):735.

Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 Apr 6;140(7):533-7.

Klimant E, Wright H, Rubin D, et al. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr Oncol. 2018;25(2):139-148.

Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010 Jul 7;5(7):e11414.

Robitaille L, Mamer OA, Miller WH Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009 Feb;58(2):263-9.; Prier M, Carr AC, Baillie N. No Reported Renal Stones with Intravenous Vitamin C Administration: A Prospective Case Series Study. Antioxidants (Basel). 2018 May 21;7(5):68.

Quinn J, Gerber B, Fouche R, et al. Effect of High-Dose Vitamin C Infusion in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient. Case Rep Med. 2017;2017:5202606.

Chen P, Yu J, Chalmers B, et al. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2012 Apr;23(4):437-44.

Lin ZY, Chuang WL. Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother. 2010 May;64(5):348-51.

Takemura Y, Satoh M, Satoh K, et al. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun. 2010 Apr 2;394(2):249-53.

Ghavami G, Sardari S. Synergistic Effect of Vitamin C with Cisplatin for Inhibiting Proliferation of Gastric Cancer Cells. Iran Biomed J. 2020 Mar;24(2):119-27.

Wang Q, Xu Q, Wei A, et al. High dose vitamin C inhibits proliferation of breast cancer cells through reducing glycolysis and protein synthesis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 May 25;48(3):296-302. Chinese.

Gregoraszczuk EL, Zajda K, Tekla J, et al. Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells. Int J Vitam Nutr Res. 2021 Jun;91(3-4):293-303.

Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9.

Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011 Jun 1;50(11):1610-9.

Jacobs C, Hutton B, Ng T, et al. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015 Feb;20(2):210-23.

van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, et al. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients. 2019 Apr 28;11(5):977.

Günes-Bayir A, Kiziltan HS. Palliative Vitamin C Application in Patients with Radiotherapy-Resistant Bone Metastases: A Retrospective Study. Nutr Cancer. 2015;67(6):921-5.

Carr AC, McCall C. The role of vitamin C in the treatment of pain: new insights. J Transl Med. 2017;15(1):77.

Błasiak J, Gloc E, Woźniak K, et al. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact. 2002 Apr 20;140(1):1-18.

Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 Feb 5;6(222):222ra18.

Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12.

Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014;4:283.

Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007 Feb;22(1):7-11.

Mansoor F, Kumar S, Rai P, et al. Impact of Intravenous Vitamin C Administration in Reducing Severity of Symptoms in Breast Cancer Patients During Treatment. Cureus. 2021 May 6;13(5):e14867.

Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer. 2014 May;50(7):1223-31.

Ou J, Zhu X, Zhang H, et al. A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer. Integr Cancer Ther. 2020 Jan-Dec;19:1534735419895591.

Ou J, Zhu X, Chen P, et al. A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer. J Adv Res. 2020 Mar 17;24:175-182.

Chakraborthy A, Ramani P, Sherlin HJ, et al. Antioxidant and pro-oxidant activity of Vitamin C in oral environment. Indian J Dent Res. 2014 Jul-Aug;25(4):499-504.

Petronek MS, Stolwijk JM, Murray SD, et al. Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy. Redox Biol. 2021 Jun;42:101864.

Putchala MC, Ramani P, Sherlin HJ, et al. Ascorbic acid and its pro-oxidant activity as a therapy for tumours of oral cavity - a systematic review. Arch Oral Biol. 2013 Jun;58(6):563-74.

Doskey CM, Buranasudja V, Wagner BA, et al. Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016 Dec;10:274-284.

Satheesh NJ, Samuel SM, Büsselberg D. Combination Therapy with Vitamin C Could Eradicate Cancer Stem Cells. Biomolecules. 2020;10(1):79.

Michels N, van Aart C, Morisse J, et al. Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol. 2021 Jan;157:103177.

Mikirova NA, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res. 2010 Jan 18;2:2.

Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis. Medicine (Baltimore). 2020 Dec 11;99(50):e23486.

Mikirova N, Casciari J, Rogers A, et al. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012 Sep 11;10:189.

Mikirova NA, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res. 2010 Jan 18;2:2.

Carr AC, Cook J. Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge. Front Physiol. 2018;9:1182.

The Riordan IVC Protocol for Adjunctive Cancer Care Intravenous Ascorbate as a Chemotherapeutic and Biological Response Modifying Agent (februari 2013). https://riordanclinic.org/wp-content/uploads/2015/11/RiordanIVCprotocol_...